 BOSTON, Aug. 05, 2021 GLOBE NEWSWIRE -- Galecto, Inc. NASDAQ: GLTO, a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter ended June 30, 2021. 